Clinical Trial Update: A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating HS-10241 in combination with almonertinib is comparing it to platinum-based chemotherapy in advanced non-small cell lung cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• HS-10241

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN